Martin L. Katz

Prof. Martin L. Katz

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
MKMartin L. Katz
Martin L. Katz
WRW.Gerald Robison
W.Gerald Robison

17 June 2014 in Journal of Neuroscience Research
Verified
Journal Article
Open access
PDF file
MKMartin L. Katz
Martin L. Katz
JCJoan R. Coates
Joan R. Coates
CSChristine M. Sibigtroth
Christine M. Sibigtroth
JTJacob D. Taylor
Jacob D. Taylor
MCMelissa Carpentier
Melissa Carpentier
COCharles A. O'NEill
Charles A. O'NEill
Using a canine model of classical late‐infantile neuronal ceroid lipofuscinosis (CLN2 disease), a study was conducted to evaluate the potential pharmacological activity of recombinant human tripeptidyl peptidase‐1 (rhTPP1) enzyme replacement therapy administered directly to the cerebrospinal fluid (CSF). CLN2 disease is a hereditary neurodegenerative disorder resulting from mutations in CLN2, which encodes the soluble lysosomal enzyme tripeptidyl peptidase‐1 (TPP1). Infants with mutations in both CLN2 alleles develop normally but in the late‐infantile/early‐childhood period undergo progressive neurological decline accompanied by pronounced brain atrophy. The disorder, a form of Batten disease, is uniformly fatal, with clinical signs starting between 2 and 4 years of age and death usually occurring by the early teenage years. Dachshunds homozygous for a null mutation in the canine ortholog of CLN2 (TPP1) exhibit a similar disorder that progresses to end stage at 10.5–11 months of age. Administration of rhTPP1 via infusion into the CSF every other week, starting at approximately 2.5 months of age, resulted in dose‐dependent significant delays in disease progression, as measured by delayed onset of neurologic deficits, improved performance on a cognitive function test, reduced brain atrophy, and increased life span. Based on these findings, a clinical study evaluating the potential therapeutic value of rhTPP1 administration into the CSF of children with CLN2 disease has been initiated. © 2014 The Authors. Journal of Neuroscience Research Published by Wiley Periodicals, Inc.


1 August 2010 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
DSDouglas N. Sanders
Douglas N. Sanders
FFFabiana H. Farias
Fabiana H. Farias
GJGary S. Johnson
Gary S. Johnson
VCVivian Chiang
Vivian Chiang
JCJames R. Cook
James R. Cook
MKMartin L. Katz
Martin L. Katz

22 December 2010 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MKMartin L. Katz
Martin L. Katz
FFFabiana H. Farias
Fabiana H. Farias
DSDouglas N. Sanders
Douglas N. Sanders
RZRong Zeng
Rong Zeng
SKShahnawaz Khan
Shahnawaz Khan
DODennis P. O'Brien
Dennis P. O'Brien
The childhood neuronal ceroid lipofuscinoses (NCLs) are inherited neurodegenerative diseases that are progressive and ultimately fatal. An Australian Shepherd that exhibited a progressive neurological disorder with signs similar to human NCL was evaluated. The cerebral cortex, cerebellum, and retina were found to contain massive accumulations of autofluorescent inclusions characteristic of the NCLs. Nucleotide sequence analysis of DNA from the affected dog identified a T to C variant (c.829T>C) in exon 7 of CLN6. Mutations in the human ortholog underlie a late‐infantile form of NCL in humans. The T‐to‐C transition results in a tryptophan to arginine amino acid change in the predicted protein sequence. Tryptophans occur at homologous positions in the CLN6 proteins from all 13 other vertebrates evaluated. The c.829T>C transition is a strong candidate for the causative mutation in this NCL‐affected dog. Dogs with this mutation could serve as a model for the analogous human disorder.

1 February 2015 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
PDF file
BVBrian R. Vuillemenot
Brian R. Vuillemenot
DKDerek Kennedy
Derek Kennedy
JCJonathan D. Cooper
Jonathan D. Cooper
AWAndrew M.S. Wong
Andrew M.S. Wong
SSSarmi Sri
Sarmi Sri
COCharles A. O'Neill
Charles A. O'Neill